A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2014
At a glance
- Drugs Atopaxar (Primary) ; Metformin
- Indications Diabetes mellitus; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 31 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2010 New trial record